Abstracts tagged "Disease Activity"

Abstract Number: 1762 • 2018 ACR/ARHP Annual Meeting
Plasma iC3b Level As a Biomarker of Disease Relapse in ANCA-Associated Vasculitis
Catherine E. Najem¹, Martin Schmidt², Chad Stiening³, David Cuthbertson⁴, Simon Carette⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol Langford⁸, Carol A. McAlear⁹, Paul A. Monach¹⁰, Larry W. Moreland¹¹, Christian Pagnoux¹², Philip Seo¹³, Ulrich Specks¹⁴, Antoine G. Sreih¹, Steven R. Ytterberg¹⁵ and Peter A. Merkel^16,17, ¹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Kypha, Inc., St. Louis, MO, ³Kypha, Inc., St Louis, MO, ⁴Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁸Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁹Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ¹⁰Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹¹Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹²Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹³Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁴Mayo Clinic College of Medicine, Rochester, MN, ¹⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ¹⁶Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁷Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose:C3, the central protein of the complement cascade, participates in an amplification loop that can lead to complement deposition and host tissue damage. If elevated,…
Abstract Number: 2401 • 2018 ACR/ARHP Annual Meeting
The Effects of a Gluten-Free Diet in Juvenile Idiopathic Arthritis – a Pilot Study
Anjali Sura¹, Stacey Fogarty-Brown² and Meredith Riebschleger³, ¹Pediatric Rheumatology, University of Michigan, Ann Arbor, MI, ²Pediatrics, University of Michigan, Ann Arbor, MI, ³Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI
Background/Purpose: The caregivers of children with juvenile idiopathic arthritis (JIA) frequently ask about the utility of dietary restrictions. Some patients and physicians report a good…
Abstract Number: 2600 • 2018 ACR/ARHP Annual Meeting
Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial
Laure Gossec¹, Bruce Kirkham², Proton Rahman³, Philip Helliwell⁴, Alice B Gottlieb⁵, Wolf-Henning Boehncke⁶ and Chenglong Han⁷, ¹Rheumatology Department, Hôpital Pitié Salpêtrière, Paris 06 University, Paris, France, ²Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ³Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ⁴LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁵Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY, ⁶Department of Dermatology and Venereology, Geneva University Hospital, Geneva, Switzerland, ⁷Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To evaluate the effect of guselkumab (GUS) on Health-Related Quality of Life (HRQOL) and correlate changes of HRQOL and disease activity in patients with…
Abstract Number: 2929 • 2018 ACR/ARHP Annual Meeting
Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
Michelle Petri¹, Daniel Goldman¹ and Laurence S Magder², ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Outcome measures that combine control of SLE activity and prednisone reduction are clinically relevant. A clinical goal in SLE is to reduce risk of…
Abstract Number: 300 • 2018 ACR/ARHP Annual Meeting
Built-in-Electronic-Medical-Record Disease Activity Calculators and Treat-to-Target in Rheumatoid Arthritis
Arundathi Jayatilleke¹ and Scott Pompa², ¹Department of Rheumatology, Drexel Rheumatology, Philadelphia, PA, ²Rheumatology, Drexel Rheumatology, Philadelphia, PA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory arthritis that, if undertreated, can lead to cumulative damage and disability. The goal of treatment is to…
Abstract Number: 567 • 2018 ACR/ARHP Annual Meeting
Non-Surgical Periodontal Therapy Plus Short-Term Antibiotic Treatment May Improve Clinical Disease Activity: A Pilot Study in Difficult to Treat Rheumatoid Arthritis
Burkhard Moeller¹, Philip Bender², Sigrun Eick², Kim Midwood³, Jan Potempa⁴, Stephan Reichenbach⁵, Anja Schwenzer³, Peter M. Villiger⁶ and Alicia Wong³, ¹Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ²School of Dental Medicine, University of Bern, Bern, Switzerland, ³Kennedy Institute for Rheumatology, Oxford University, Oxford, United Kingdom, ⁴Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland, ⁵Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ⁶University of Bern, Bern, Switzerland
Background/Purpose: Autoimmunity against citrullinated peptides is a hallmark of rheumatoid arthritis (RA). Chronic periodontitis (CP) is a known major source of citrullinated peptides. Here, we…
Abstract Number: 1097 • 2018 ACR/ARHP Annual Meeting
Spatial-Time Cluster Analysis of SLE Disease Activity
George Stojan¹, Anton Kvit², Frank Curriero² and Michelle Petri³, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Bloomberg School of Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Cluster detection is an essential tool in the public health domain with the goal of detecting anomalous clusters of disease cases. We performed a…
Abstract Number: 1607 • 2018 ACR/ARHP Annual Meeting
Achievement of Cdapsa Low Disease Activity or Remission Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psa in Subjects Treated with Apremilast
Laura C. Coates¹, Philip J. Mease², Frank Behrens³, Ana-Maria Orbai⁴, Alexis Ogdie⁵, Michele Brunori⁶, Lichen Teng⁶, Benoit Guerette⁶ and Josef S. Smolen⁷, ¹University of Oxford, Oxford, United Kingdom, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Celgene Corporation, Summit, NJ, ⁷Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Therapeutic targets for psoriatic arthritis (PsA) include the achievement of remission (REM) or low disease activity (LDA), measured by the Clinical Disease Activity Index…
Abstract Number: 1763 • 2018 ACR/ARHP Annual Meeting
Characterizing the Gut and Plasma Metabolomes in Patients with ANCA-Associated Vasculitis
Catherine E. Najem¹, Jung-Jin Lee², Ceylan Tanes², Cassidy Strange², Elliot Friedman², Antoine G. Sreih¹, Rennie L. Rhee¹, Abdallah Geara³, Hongzhe Li⁴, Kyle Bittinger², James D. Lewis⁵, Gary Wu⁵ and Peter A. Merkel⁴, ¹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Nephrology and Hypertension, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, ⁵Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA
Background/Purpose:To explore the mechanisms by which an altered gut microbiota might predispose to ANCA-associated vasculitis (AAV), a comprehensive metabolic profiling of fecal and plasma bile…
Abstract Number: 2431 • 2018 ACR/ARHP Annual Meeting
Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis
Chelsey J F Smith¹, Arthur Kavanaugh² and Christina D Chambers³, ¹Rheumatology, University of California San Diego, La Jolla, CA, ²University of California, San Diego, School of Medicine, La Jolla, CA, ³University of California San Diego Department of Pediatrics, La Jolla, CA
Background/Purpose: The goal of this prospective cohort study is to add to the limited data on birth outcomes in psoriatic arthritis (PsA) and ankylosing spondylitis…
Abstract Number: 2625 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitor Reduces ASDAS Faster and More Stable in Ankylosing Spondylitis Patients: Results from a Real World Prospective Cohort Managed By Smart Phone System
Xiaojian Ji, Jian Zhu, Jianglin Zhang and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose: The Smart-phone Spondyloarthritis Management System (SpAMS) is a mobile health tool, specifically designed to conduct prospective clinical studies on SpA/AS in China, using real-world…
Abstract Number: 2949 • 2018 ACR/ARHP Annual Meeting
African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in B Cells and TLR7/8 Pathways
Samantha Slight-Webb¹, Miles C. Smith¹, Holden T. Maecker², Paul J. Utz³, Joel M. Guthridge¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Stanford University, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder with a heterogeneous clinical presentation and periods of waxing and waning disease. Heterogeneity in SLE is…
Abstract Number: 9L • 2017 ACR/ARHP Annual Meeting
Circulating Type I, II and III Interferons (IFNs) Associate with IFN-Scores, but Define Distinct Subsets of Active SLE
Vilija Oke¹, Iva Gunnarsson¹, Jessica M. Dorschner², Agneta Zickert¹, Timothy B. Niewold³ and Elisabet Svenungsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Colton Center for Autoimmunity, New York University, New York, NY

Background/Purpose: Serum induced IFN gene expression (IFN-score) is considered a golden standard to assess IFN activity in SLE. So far, IFN-scores have not been compared…
Abstract Number: 2533 • 2017 ACR/ARHP Annual Meeting
Current Psa Therapy Impacts the Relationship between the Degree of Skin Invlovment and Joint Activity
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Simultaneous control of joint symptoms and degree of skin involvement has been linked to improvement in health-related quality of life in patients with coexistent…
Abstract Number: 2910 • 2017 ACR/ARHP Annual Meeting
Comparison of Clinical and Ultrasound Measures of Disease Activity in a Large National ‘Real Life’ Cohort of RA Patients
Pascal Zufferey¹, Delphine Couvoisier², Hans Ruedi Ziswiler³, Laure Brulhart⁴, Giorgio Tamborrini⁵, Michael Nissen⁶, Adrian Ciurea⁷, Burkhard Moeller⁸, Maria Antonietta D'Agostino^9,10 and Axel Finckh², ¹Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ²geneva university hospital, Geneva, Switzerland, ³Osteorheuma, Bern, Switzerland, ⁴médecine, hôpital neuchateulois, La chaux de fond, Switzerland, ⁵UZR, Basel, Switzerland, ⁶rheumatology, geneva university hospital, Geneva, Switzerland, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁸Department for Rheumatology, Immunology and Allergology, University Hospital of Bern, Bern, Switzerland, ⁹Department of Rheumatology, Assistance publique-Hôpitaux de Paris Ambroise Paré Hospital, Boulogne-Billancourt , Université Versailles Saint Quentin en Yvelines, Paris, France, ¹⁰University of Paris, Paris, France
Background/Purpose: Clinical measures of disease activity, such as the DAS-score and ultrasound (US) scores of disease activity can be sometimes yield discordant results. Little research…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].